(Q28469348)

English

Building clinical trials capacity for tuberculosis drugs in high-burden countries

scientific article

In more languages

edit

Statements

instance of

scholarly article

0 references

title

Building clinical trials capacity for tuberculosis drugs in high-burden countries (English)

0 references

0 references

5

Richard Chaisson

0 references

Christian Lienhardt

series ordinal

3

object named as

Christian Lienhardt

0 references

author name string

Neil Schluger

series ordinal

1

0 references

Unni Karunakara

series ordinal

2

0 references

Thomas Nyirenda

series ordinal

4

0 references

language of work or name

English

0 references

publication date

6 November 2007

0 references

published in

PLOS MEDICINE

0 references

volume

4

0 references

issue

11

0 references

page(s)

e302

0 references

copyright license

Creative Commons Attribution 4.0 International

start time

6 November 2007

1 reference

stated in

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062480

retrieved

19 March 2017

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062480

retrieved

29 September 2017

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062480

retrieved

29 September 2017

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062480

retrieved

2 June 2018

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062480

retrieved

27 November 2018

Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062480

retrieved

27 November 2018

Identifiers

DOI

10.1371/JOURNAL.PMED.0040302

0 references

PMC publication ID

2062480

0 references

PubMed publication ID

17988170

0 references

ResearchGate publication ID

5859014

0 references

(Q28469348)

Building clinical trials capacity for tuberculosis drugs in high-burden countries

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)